{"prompt": "['11.2 Translational Scheduling', '45', '11.3 Translational Materials and Methods', '46', '11.3.1 Sample Collection, handling and shipment', '46', '11.3.2 Analysis', '46', '11.4 Translational Statistics', '47', '12.0 BIBLIOGRAPHY', '48', '13.0 Supporting documentation and additional documents', '52', 'Appendix I SAE form FAC-SIMILE', '52', 'Appendix II EORTC QLQ-C30 and QLQ-H&N35', '60', 'Appendix III Unacceptable toxicities', '64', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '5']['1.0 TRIAL SUMMARY', 'Phase I - II trial of the combination of cyclophosphamide, RT, and Avelumab in relapsed/metastatic', 'HNSCC (R/M-HNC).', 'Patients pretreated with at least one line therapy containing platinum, fluorouracil, and Cetuximab.', 'Treatment consists of metronomic cyclophosphamide 50 mg daily without drug free break,', 'avelumab 10 mg/kg dl and 15 q 29, and radiotherapy in one or three daily fractions up to 8 Gy', 'maximum dose, starting at day 8.', 'The aim of the study is to reverse tumor immune-escape by:', '1. Provide a self-vaccination with radiotherapy', '2. Inhibit the immunosuppressive CD4+ CD25+ FoxP3+ Treg cells with metronomic', 'cyclophosphamide', '3. Reactivate the effector T cell by the inhibition of PD-1 - PD-L1 axis with avelumab.', 'Due to the supposed biological effects of the present trial, an ancillary translational study is needed', \"and will be extended to all the patients' population enrolled.\", '2.0 BACKGROUND & RATIONAL', '2.1 Unmet medical need and trial rational', '2.1.1 Unmet clinical need', 'Platinum resistant relapsed/metastatic HNC (RM-HNC) shows a dismal prognosis. No approved', 'second line are yet available.', 'Methotrexate is sometimes used following platinum failure or in patients not fit enough for', 'platinum therapy, but this agent has not demonstrated any Overall Survival (OS) improvement.', 'Second line treatment with methotrexate was recently compared to afatinib in a randomized trial.', 'Response rate was low in both arms (6.5% vs 10% respectively). Progression free survival favoured', 'significantly afatinib, but the difference was clinically irrelevant1.', 'The EGFR-targeting monoclonal antibody cetuximab (plus platinum-based chemotherapy) was', 'approved in the US and Europe (NCCN. Clinical Practice Guidelines in Oncology. Head and Neck', 'Cancer) in first line therapy of relapsed metastatic disease.', '2', 'However, only FDA approved cetuximab in second-line but not EMA, due to the limited benefit', 'observed.', 'Taxanes have also been used. However, no study has been able to show that these agents improve', 'OS.', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '6']['The new insight in immunology as well as the understanding of the immunologic effects both of', 'chemotherapy and radiotherapy, paves the way to a novel approach to cancer treatment based on the', 'strengthening of host natural defence rather than to the direct tumor aggression.', 'Phase II and III trials showed improvement in os and quality of life in patients treated with anti-', 'PD-1 regardless the number of prior chemotherapy lines. Results showed also a limited but', 'significant number of long-term survivors. However, most patients do not achieve an objective', 'response or relapse within one year from treatment start. This outcome reflects the limit of targeting', 'a single pathway in the achievement of major results in this setting of patients3-4', '2.1.2 Rational of the trial', 'Hereby we propose a phase I - II trial in RM-HNC based on pharmacologic and physic', 'interventions related to each other facing immunology as a system rather than a single pathway,', 'theoretically able to restore immune competence toward the tumor. The immune suppressive', 'mechanisms that could be affected by this study and how the experimental approach could inhibit', 'them, are listed below:', 'e', 'PD-1 - PD-L1 axis is widespread among immune cell family including CTL, Treg, NK,', 'NKT, APC and others\u00b3 showing, for example, opposite effect in CD8+ CTL (inhibitory signal)6 or', 'in CD4+ CD25+ Foxp3+ (activating signal\u00b2.', 'Depletion of Treg results in tumor regression, in experimental models 8-9 The effect seems', 'to', 'be dependent on the extent of Treg suppression10', 'Avelumab is a fully human anti-PD-L1 IgG1 monoclonal antibody. It enables the', 'activation of T-cells and the adaptive immune system by inhibiting PD-1 - PD-L1 axis, induces', 'antibody-dependent cell-mediated cytotoxicity (ADCC) and engages the innate immune system', 'Low dose cyclophosphamide (metronomic cyclophosphamide), selectively reduce Treg', 'population both in experimental models and in humans, but it does not affect effector T cells 12', 'PD-1 - PD-L1 axis enhances and sustains Foxp3 expression and the suppressive function of', 'inducible Tregs (iTrge) The blockade of the PD1 - PDL1 axis by Avelumab may have an opposite', 'effect.', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '7']\n\n###\n\n", "completion": "END"}